Matrix metalloproteinase (MMP)-10 aggravates podocyte injury in glomerulonephritis

Area of Science:

• Nephrology
• Molecular Biology
• Biochemistry

Background:

• Podocytes are crucial for the glomerular filtration barrier.
• Podocyte guanylyl cyclase-A (GC-A) plays a key role in severe albuminuria.
• Matrix metalloproteinase-10 (MMP-10) is upregulated in GC-A knockout mice with aldosterone treatment.

Purpose of the Study:

• To investigate the role of MMP-10 in glomerular injury and glomerulonephritis.
• To analyze the impact of combined GC-A and MMP-10 deficiency on kidney damage.
• To explore the in vitro effects of MMP-10 on podocyte inflammation and injury.

Main Methods:

• Utilized MMP-10 knockout mice in anti-glomerular basement membrane (GBM) nephritis models.
• Created systemic and podocyte-specific GC-A/MMP-10 double knockout mouse models.
• Examined inflammatory mRNA changes in MMP-10-manipulated mouse podocytes stimulated with TNF-α.

Main Results:

• MMP-10 is highly expressed in human glomerulonephritis kidneys.
• MMP-10 knockout mice exhibited reduced albuminuria and inflammation in anti-GBM nephritis.
• Combined GC-A and MMP-10 knockout mice showed improved kidney function and preserved nephrin expression.
• In vitro, MMP-10 overexpression exacerbated TNF-α-induced inflammation, while knockdown mitigated it.
• Activated MMP-10 cleaved nephrin, contributing to podocyte injury.

Conclusions:

• GC-A deficiency leads to MMP-10 upregulation and nephrin loss.
• Systemic MMP-10 deletion ameliorates GC-A-induced podocyte injury.
• MMP-10 is a potential therapeutic target for GC-A-related kidney diseases.